Abstract:The aim of the present study was to investigate the relationship among serum mean platelet volume (MPV) levels, benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and metabolic syndrome (MetS), and study the potential role of serum MPV levels in BPH/LUTS progression in an indirect manner. A total of 551 Men aged 45-year-old or older with moderate to severe LUTS due to benign prostatic enlargement (BPE) were recruited into the present study by consecutive routine physical examination programs. Urologic evaluation included transrectal ultrasound, International Prostate Symptom Score and maximum urinary flow rate (Qmax). Overnight fasting venous blood specimens were collected and serum levels of prostate-specific antigen, fasting blood glucose, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, triglyceride and C-reactive protein were recorded. In addition, mean platelet volume was determined by automated hematology analyzer. We divided subjects into two groups according to the presence of MetS. We also took the MPV values as a categorical variable and divided subjects into two groups (≥11.8 or <11.8 fL) or four groups according to the different levels of MPV (9.3–11.0, 11.1–11.5, 11.6–11.9, 12.0–12.5 and ≥12.5 fL). The clinical characteristics and parameters of BPH/LUTS in different groups were measured and compared to identify their relationships. MetS was diagnosed in 37.0% of the subjects. There were significant interactive correlation among the number of positive MetS components, CRP, MPV and parameters of BPH/LUTS. The ratio of PV ≥31 mL and Qmax <10.6 mL/s were positively correlated with the increased level of MPV. Additionally, the odds ratio (OR) in relation to PV ≥31 mL and Qmax <10.6 mL/s significantly rose as the level of MPV increased after adjusting for age, with a suggesting of a threshold effect at 12.0–12.5 fL for PV ≥31 mL (OR 2.678, 95% CI, 1.425–5.035) and at >12.5 fL for Qmax <10.6 mL/s (OR 3.190, 95% CI, 1.768–5.755). However, only the value of MPV more than 12.5 fL still showed statistically significant effect on Qmax <10.6 mL/s after adjusting for age and the presence of MetS (OR 2.164, 95% CI, 1.162–4.032). Our results add to the evidence that chronic inflammation is a candidate mechanism at the crossroad between MetS and BPH/LUTS, and the presence of elevated MPV may serve as a predictor of MetS-induced inflammation in the progression of BPH/LUTS.

The Association Between Metabolic Syndrome and Benign Prostatic Hyperplasia: a Systematic Review and Meta-Analysis

The Association Between Metabolic Syndrome And Benign Prostatic Hyperplasia: A Systematic Review And Meta-Analysis

The Relationship Between the Clinical Progression of Benign Prostatic Hyperplasia and Metabolic Syndrome: A Prospective Study

Relationship Between Metabolic Syndrome and Predictors for Clinical Benign Prostatic Hyperplasia Progression and International Prostate Symptom Score in Patients with Moderate to Severe Lower Urinary Tract Symptoms.

The Correlation Between Metabolic Syndrome and Benign Prostatic Hyperplasia in Men over 50 Years O1d

The Underlying Mechanism of Metabolic Syndrome on Benign Prostatic Hyperplasia and Prostate Volume.

Correlation Between Metabolic Syndrome and Clinical Progression in Patients with Benign Prostatic Hyperplasia

Relationship between metabolic syndrome and benign prostatic hyperplasia

Relationship Between Benign Prostatic Hyperplasia and Metabolic Syndrome

Correlation between Benign Prostatic Hyperplasia and Metabolic Syndrome

Metabolic Syndrome and Benign Prostatic Hyperplasia: Evidence of a Potential Relationship, Hypothesized Etiology, and Prevention

Metabolic Syndrome is Not Associated with Prostate Cancer Recurrence: A Retrospective Analysis of a Chinese Cohort.

The Association Between Metabolic Syndrome and Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in Aging Males: Evidence Based on Propensity Score Matching

Relationship between lower urinary tract symptoms and metabolic syndrome in a Chinese male population

Body mass index and risk of BPH: a meta-analysis

The association of metabolic syndrome and its components with serum prostate-specific antigen levels

Metabolic syndrome and the risk of prostate cancer

Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome

The Relationship between Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms and Mean Platelet Volume: The Role of Metabolic Syndrome

The Association Between Metabolic Syndrome and Advanced Prostate Cancer in Chinese Patients Receiving Radical Prostatectomy

AB075. The relationship between benign prostatic hyperplasia/lower urinary tract symptoms and mean platelet volume: the role of metabolic syndrome